SOC 2 · Digital health & life sciences
SOC 2 Readiness for Clinical Research Organizations
SOC 2 readiness for a CRO is usually the fastest credible answer to a US sponsor's information-security questionnaire, more than a general trust signal. The trigger is a first US sponsor contract that names SOC 2 explicitly, or an RFI that keeps asking for independent evidence your policy set alone cannot provide. We scope the readiness work around your study-delivery systems, not just corporate IT, so the resulting report actually answers the question sponsors are asking.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What SOC 2 scope has to include for a CRO
A report scoped only to corporate IT misses the systems a sponsor actually cares about.
Study-delivery systems, not just the corporate network
EDC, eTMF and CTMS platforms your organization operates or configures need to sit inside the audit boundary if the report is going to answer a sponsor's real question.
Remote-monitoring access controls
How monitor accounts into site EHRs are provisioned and reviewed, since access management is a Trust Services Criteria control area sponsors expect to see addressed.
Subcontractor oversight
Evidence that central labs, ePRO vendors and other subcontractors touching trial data are themselves reviewed, since a SOC 2 report increasingly needs to show vendor management as a functioning control.
Incident response readiness
A documented, tested incident response process, including how it interacts with safety-reporting obligations that keep running during an incident.
Regulatory map
Why SOC 2 answers a specific sponsor expectation
SOC 2 sits alongside, not instead of, the GCP-driven obligations a CRO already carries.
GCP vendor qualification expectations
Sponsor qualification audits tied to Division 5's good clinical practice requirements increasingly treat an independent SOC 2 report as strong evidence of a functioning security program, shortening the rest of the review.
The US business-associate position
A CRO is typically not a business associate under US rules, and SOC 2 is often the evidence a US sponsor accepts in place of a BAA-style compliance package it cannot actually require.
PIPEDA's safeguards principle
PIPEDA expects safeguards proportionate to the sensitivity of the personal information held, and a SOC 2 report gives an organization independent evidence that those safeguards operate as described.
What goes wrong
What a poorly scoped SOC 2 exposes a CRO to
A SOC 2 report that scopes out the systems sponsors actually care about creates a false sense of readiness.
A report that skips study-delivery systems
A SOC 2 covering only corporate email and HR systems does not answer a sponsor's question about how EDC and eTMF access is controlled, forcing a second, separate review anyway.
Continuity evidence a sponsor expects but doesn't find
The 2020 ransomware attack on eResearchTechnology made continuity a standard sponsor question, and a Type 2 report without tested incident-response evidence leaves that question unanswered.
Vendor management gaps inside the audit boundary
A missing or superficial subcontractor oversight control is one of the more common findings in a Type 2 observation period for organizations that rely heavily on central labs and ePRO vendors.
A timeline mismatch with sponsor deadlines
Starting Type 2 readiness only after a sponsor RFI arrives leaves the organization explaining an in-progress observation period instead of presenting a finished report.
Our soc 2 for clinical research organizations
What our SOC 2 readiness work covers for a CRO
Readiness scoped and sequenced around your actual eClinical systems and sponsor timeline.
Scoping workshop
We define which systems belong inside the audit boundary, weighing which Trust Services Criteria actually matter to your sponsor relationships.
Gap assessment
A benchmark of current controls against SOC 2 requirements, covering access control, change management, incident response and vendor oversight specifically.
Control implementation
Building or documenting the controls needed to close gaps, sequenced to avoid disrupting active studies or validated systems.
Type 1 or Type 2 audit support
Coordination through the formal audit, whether a point-in-time Type 1 report or a Type 2 observation period, with evidence collection built into the process rather than assembled at the end.
Ongoing monitoring between cycles
Continued evidence collection and control review between audit cycles, so the next renewal does not start from a standing start.
How the engagement runs
How SOC 2 readiness runs at a CRO
We lead the engagement and use an AI-driven compliance platform to handle policies, evidence and monitoring, so your team makes only the changes that actually matter.
Step 1
Gap assessment
We benchmark your current controls against SOC 2 and hand you a clear, prioritized plan scoped to study-delivery systems.
Step 2
Design and implement
We build the controls your organization needs; evidence is captured continuously as the work progresses rather than reconstructed later.
Step 3
Certification audit
We prepare your team, run a mock audit, and support you through the formal attestation with the auditor of record.
What it costs
What drives SOC 2 readiness cost for a CRO
Cost depends on how many systems fall inside the audit boundary, whether the report needs to cover remote-monitoring access and subcontractor oversight, and whether you are pursuing a Type 1 or a Type 2 report. Including study-delivery systems typically adds scope compared with a corporate-IT-only report, but it is the scope sponsors actually want to see.
Get a tailored quote once we understand your systems inventory and which sponsor timeline the readiness work needs to meet.
Clinical Research Organizations: SOC 2 questions, answered
Most US sponsors accept a current Type 2 report as strong evidence, often shortening or replacing large sections of an information-security questionnaire. Some sponsors still ask supplementary questions specific to trial systems, so a Type 2 report reduces the work rather than eliminating it entirely.
Study-delivery systems should be inside the boundary, since that is what sponsors actually care about, alongside the corporate IT environment that supports them. A report scoped only to email and HR systems will not satisfy a sponsor asking how EDC or eTMF access is controlled.
Gap assessment and control implementation typically take a few months, and a Type 2 report additionally requires an observation period of several months during which controls must operate as documented. Scheduling around active study milestones keeps the process from disrupting trial delivery.
No. SOC 2 provides independent verification that controls operate as described, but the organization still needs the underlying access-control, audit-trail and retention policies a sponsor qualification audit checks for directly.
If Phase 1 systems handle data relevant to the studies a sponsor is qualifying you for, include them, since excluding a major operational area can prompt a sponsor to ask why. Where Phase 1 work is entirely separate from a given sponsor's studies, scoping it out can be reasonable.
A Type 1 report, which attests to control design at a point in time, can bridge the gap while the Type 2 observation period completes. Being transparent about the timeline, rather than overstating readiness, tends to land better with sponsor security reviewers than it might seem.
More for clinical research organizations
Other services for this niche
- Privacy & security for clinical research organizations — overview
- Virtual CISO
- Virtual Privacy Officer
- Penetration Testing
- Incident Response Planning
- Privacy & Security Policy Development
- Privacy & Security Training
- Vendor Security Review & Questionnaire Support
- ISO 27001 Readiness
- AI Privacy Impact Assessment
- HIPAA Readiness
About this service
Answers & guides
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.